newsfilter
← Latest News
GlobeNewswire·

Ascentage Pharma Presents Updated Clinical Data for Olverembatinib as Second-Line Therapy in CML-CP at ASCO 2026

  • Ascentage Pharma presented updated efficacy & safety data for olverembatinib as second-line therapy in chronic-phase chronic myeloid leukemia (CML-CP) at the 2026 ASCO Annual Meeting.
  • At cycle 24, patients treated with olverembatinib achieved a 91.3% complete cytogenetic response (CCyR) rate & a 60.9% major molecular response (MMR) rate.
  • Responses deepened over time while the drug maintained a stable & manageable safety profile with no new safety signals identified.
  • Olverembatinib is the first third-generation BCR-ABL1 inhibitor approved in China & is jointly commercialized there by Ascentage Pharma & Innovent Biologics.
  • The drug is currently approved in China for adult patients with TKI-resistant CML-CP or CML-AP harboring T315I mutations, as well as those resistant or intolerant to first- & second-generation TKIs.
  • All approved indications for olverembatinib are now covered by the China National Reimbursement Drug List (NRDL).
  • Ascentage Pharma is conducting three global registrational Phase III studies for olverembatinib in CML-CP, Ph+ ALL, & SDH-deficient GIST, with two studies cleared by the FDA & EMA.
  • Ascentage Pharma has signed an exclusive option agreement with Takeda for global rights to olverembatinib outside of mainland China, Hong Kong, Macau, & Taiwan.
  • In the study of 42 evaluable patients, the best CCyR rate was 76.2% & the best MMR rate was 47.6% at study cutoff, with high response rates observed in patients previously treated with second-generation TKIs.
  • Treatment-related adverse events occurred in 89.4% of patients, primarily including skin hyperpigmentation, hyperuricemia, & increased creatine phosphokinase, with grade ≥3 hematologic toxicities being recoverable via supportive treatment.
  • The Company's second approved product, lisaftoclax, is a Bcl-2 inhibitor approved in China for CLL/SLL patients previously treated with BTK inhibitors.
  • Four global registrational Phase III trials for lisaftoclax are ongoing, including the FDA- & EMA-cleared GLORA study in combination with BTK inhibitors.